Kazia Therapeutics(KZIA.US)

Last Updated 19:00:00 ET
longbridge loading

Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy

Tip Ranks·
US
KZIA
+13.88%
US
CELC
-1.05%
Tip Ranks·
US
KZIA
+13.88%
US
CELC
-1.05%

Kazia Therapeutics Appoints James Levine as Chief Financial Officer | KZIA Stock News

StockTitan·
US
KZIA
+13.88%
StockTitan·
US
KZIA
+13.88%

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer | KZIA Stock News

StockTitan·
US
KZIA
+13.88%
StockTitan·
US
KZIA
+13.88%

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform | KZIA Stock News

StockTitan·
US
KZIA
+13.88%
US
LABU
+2.37%
US
BBH
-0.17%
StockTitan·
US
KZIA
+13.88%
US
LABU
+2.37%
US
BBH
-0.17%

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform | KZIA Stock News

StockTitan·
US
KZIA
+13.88%
US
IBB
+0.10%
US
XBI
+0.79%
StockTitan·
US
KZIA
+13.88%
US
IBB
+0.10%
US
XBI
+0.79%
© 2026 Longbridge｜Disclaimer